Table 1.
Demographic and baseline characteristics (n = 84)
| Characteristic | Value |
|---|---|
| Age, yr | 57.7 (31–82) |
| Dose of fulvestrant | |
| 250 mg | 24 (29) |
| 500 mg | 60 (71) |
| Initial stage of breast cancer | |
| Stage I–III | 67 (80) |
| Stage IV | 17 (20) |
| No. of previous endocrine therapy | |
| 1 | 18 (21.4) |
| 2 | 43 (51.2) |
| 3 | 22 (26.2) |
| 4 | 1 (1.2) |
| Median (range) | 2 (1–4) |
| No. of previous chemotherapy | |
| 0 | 39 (46.3) |
| 1 | 15 (17.8) |
| 2 | 11 (13.1) |
| 3 | 6 (7.1) |
| 4 | 4 (4.8) |
| ≥ 5 | 9 (10.7) |
| Median (range) | 2 (0–11) |
| Adjuvant endocrine treatment (n = 67) | |
| Yes | 53 (79.1) |
| No | 14 (20.9) |
| Disease extent | |
| Visceral metastasis | 49 (58.3)a |
| Lung | 34 |
| Liver | 16 |
| Brain | 4 |
| Bone marrow | 4 |
| Adrenal gland | 4 |
| Other (pancreas, kidney, ovary) | 5 |
| Non-visceral metastasis | 35 (41.7) |
| Bone only | 17 |
| Bone and nodes | 11 |
| Soft tissue | 7 |
| Tumor response to fulvestrant | |
| Complete response | 0 |
| Partial response | 13 (15.5) |
| Stable disease | 21 (25.0) |
| Progressive disease | 50 (59.5) |
| Disease control rate | 34 (40.5) |
| 95% Confidence interval | 30.5–51.5 |
Values are presented as median (range) or number (%).
a
Among them, 10 patients had multiple visceral involvement.